Real-world evidence of ribociclib-induced hepatotoxicity in patients with breast cancer: a multi-center experience

Abstract Background CDK4/6 inhibitors are primarily used to treat hormone-positive HER-2 negative (HR+/ HER2-) metastatic breast cancer. Although ribociclib is generally well-tolerated, there is limited real-world data on hepatotoxicity associated with its use. Therefore, we evaluated the characteri...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Onur Baş, Bediz Kurt İnci, İmdat Eroğlu, Safa Can Efil, Seher Kaya, Pınar Kubilay Tolunay, Taha Koray Şahin, Cengiz Karaçin, Ozan Yazıcı, Mehmet Ali Nahit Şendur, Berna Ömür Çakmak Öksüzoğlu, Sercan Aksoy
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2025-11-01
coleção:	BMC Cancer
Assuntos:	CDK 4/6 inhibitor Breast cancer Ribociclib Hepatotoxicity Clinical management
Acesso em linha:	https://doi.org/10.1186/s12885-025-15181-x
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!